10-Q

U.S.

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended March 31, 2012.

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT.

For the transition period from                     to                     

Commission file number 0-27610

LCA-Vision Inc.

(Exact name of registrant as specified in its charter)

Delaware	11-2882328
(State or other jurisdiction of	(IRS Employer
incorporation or organization)	Identification No.)

7840 Montgomery Road, Cincinnati, Ohio 45236

(Address of principal executive offices)

(513) 792-9292

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).     Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one)

Large accelerated filer	¨	Accelerated filer	x
Non-accelerated filer	¨	Smaller reporting company	¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes  ¨    No  x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 18,972,134 shares as of April 19, 2012.

LCA-Vision Inc.

TABLE OF CONTENTS

Part I. FINANCIAL INFORMATION
Item 1.	Financial Statements
	Condensed Consolidated Balance Sheets (Unaudited) March 31, 2012 and December 31, 2011	3
	Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited) Three Months Ended March 31, 2012 and 2011	4
	Condensed Consolidated Statements of Cash Flows (Unaudited) Three Months Ended March 31, 2012 and 2011	5
	Notes to Condensed Consolidated Financial Statements (Unaudited)	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	13
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	18
Item 4.	Controls and Procedures	18
Part II. OTHER INFORMATION
Item 1.	Legal Proceedings	18
Item 1A.	Risk Factors	18
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	18
Item 3.	Defaults Upon Senior Securities	19
Item 4.	Mine Safety Disclosures	19
Item 5.	Other Information	19
Item 6.	Exhibits	19
	Signatures	20

2

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

LCA-Vision Inc.

Condensed Consolidated Balance Sheets (Unaudited)

(Dollars in thousands)

	March 31, 2012			December 31, 2011
Assets
Current assets
Cash and cash equivalents	$	22,914		$	18,568
Short-term investments		24,520			25,311
Patient receivables, net of allowances of $1,002 and $1,035		2,895			2,366
Other accounts receivable, net		2,945			1,974
Prepaid expenses and other		3,714			4,254
Total current assets		56,988			52,473
Property and equipment, net		9,389			10,637
Long-term investments		882			902
Patient receivables, net of allowances of $719 and $634		1,099			769
Other assets		1,349			1,652
Total assets	$	69,707		$	66,433
Liabilities and Stockholders’ Investment
Current liabilities
Accounts payable	$	9,534		$	8,103
Accrued liabilities and other		12,129			12,175
Deferred revenue		2,064			2,516
Debt obligations maturing within one year		3,015			2,978
Total current liabilities		26,742			25,772
Long-term insurance reserves, less current portion		6,183			6,264
Long-term debt obligations, less current portion		258			1,026
Other long-term liabilities		6,124			7,106
Stockholders’ investment
Common stock ($.001 par value; 25,291,637 shares issued and 18,972,134 and 18,858,147 shares outstanding, respectively)		25			25
Contributed capital		177,790			177,287
Common stock in treasury, at cost (6,319,503 shares and 6,433,490 shares, respectively)		(112,047	)		(112,910	)
Accumulated deficit		(36,041	)		(38,720	)
Accumulated other comprehensive income		673			583
Total stockholders’ investment		30,400			26,265
Total liabilities and stockholders’ investment	$	69,707		$	66,433

The notes to the Condensed Consolidated Financial Statements are an integral part of this statement.

3

LCA-Vision Inc.

Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited)

(Amounts in thousands except per share data)

	Three months ended March 31,
	2012		2011
Revenues	$	36,138	$	32,282
Operating costs and expenses
Medical professional and license fees		8,682		7,983
Direct costs of services		11,911		11,020
General and administrative expenses		3,706		3,456
Marketing and advertising		6,851		6,496
Depreciation		1,312		1,454
Restructuring charges		—		56
		32,462		30,465
Gain on sale of assets		78		163
Operating income		3,754		1,980
Net investment income and other		116		80
Income before taxes		3,870		2,060
Income tax expense		24		41
Net income	$	3,846	$	2,019
Earnings per common share
Basic	$	0.20	$	0.11
Diluted	$	0.20	$	0.11
Weighted average shares outstanding
Basic		18,895		18,743
Diluted		19,090		18,884
Comprehensive income	$	3,936	$	2,158

The notes to the Condensed Consolidated Financial Statements are an integral part of this statement.

4

LCA-Vision Inc.

Condensed Consolidated Statements of Cash Flows (Unaudited)

(Dollars in thousands)

	Three months ended March 31,
	2012			2011
Cash flows from operating activities:
Net income	$	3,846		$	2,019
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation		1,312			1,454
Provision for loss on doubtful accounts		243			155
Loss (gain) on sale of investments, net		8			(10	)
Gain on sale of property and equipment		(78	)		(163	)
Stock-based compensation		504			375
Insurance reserves		(93	)		(205	)
Changes in operating assets and liabilities:
Patient accounts receivable		(1,097	)		(290	)
Other accounts receivable		(975	)		(370	)
Prepaid expenses and other		449			1,406
Accounts payable		1,431			535
Deferred revenue, net of professional fees		(738	)		(1,142	)
Accrued liabilities and other		(319	)		1,051
Net cash provided by operations		4,493			4,815
Cash flows from investing activities:
Purchases of property and equipment		(67	)		(634	)
Proceeds from sale of assets		127			570
Purchases of investment securities		(32,203	)		(40,061	)
Proceeds from sale of investment securities		32,929			42,267
Other, net		—			8
Net cash provided by investing activities		786			2,150
Cash flows from financing activities:
Principal payments of loan		(731	)		(979	)
Shares repurchased for treasury stock		(357	)		(288	)
Proceeds from exercise of stock options		52			23
Net cash used in financing activities		(1,036	)		(1,244	)
Net effect of exchange rate changes on cash and cash equivalents		103			131
Increase in cash and cash equivalents		4,346			5,852
Cash and cash equivalents at beginning of period		18,568			19,350
Cash and cash equivalents at end of period	$	22,914		$	25,202

The notes to the Condensed Consolidated Financial Statements are an integral part of this statement.

5

LCA-Vision Inc.

Notes to Condensed Consolidated Financial Statements (Unaudited)

1. Description of Business and Accounting Policies

Description of Business

We are a provider of fixed-site laser vision correction services at our LasikPlus^® vision centers. Our vision centers provide the staff, facilities, equipment and support services for performing laser vision correction that employ advanced laser technologies to help correct nearsightedness, farsightedness and astigmatism. We currently use two suppliers for fixed-site excimer lasers: Abbott Medical Optics and Alcon, Inc. Our vision centers are supported by independent ophthalmologists and credentialed optometrists, as well as other healthcare professionals. The ophthalmologists perform the laser vision correction procedures in our vision centers, and ophthalmologists or optometrists conduct pre-procedure evaluations and post-operative follow-up care in-center. Most of our patients currently receive a procedure called Laser-Assisted In Situ Keratomileusis (“LASIK”), which we began performing in the United States in 1996.

As of March 31, 2012, we operated 52 LasikPlus^® fixed-site laser vision centers in the United States. During March 2012, one of our Baltimore, Maryland market vision center’s lease expired, and we elected not to renew. We are finalizing plans to re-open a pre- and post-operative vision center in the same market in the second quarter of 2012. Included in the 52 vision centers are two vision centers which we licensed to ophthalmologists to operate using our trademarks. Beginning in 2011, we began offering cataract, premium intraocular lens (“IOL”) and implantable collamer lens (“ICL”) services in certain of our existing markets under our new Visium Eye Institute^TM brand. Due to the nature of our operations and organization, we operate in only one business segment.

Basis of Presentation

Our Condensed Consolidated Financial Statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and, in the opinion of management, include all adjustments necessary for a fair presentation of our financial position, results of operations and cash flows for each period presented. These adjustments are of a normal and recurring nature unless otherwise disclosed herein. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to SEC rules and regulations.

We derived the Condensed Consolidated Balance Sheet as of December 31, 2011 from audited financial statements but did not include all disclosures required by U.S. GAAP. These Condensed Consolidated Financial Statements should be read in conjunction with our 2011 Annual Report on Form 10-K. Operating results for the three-month period ended March 31, 2012 are not necessarily indicative of the results expected in subsequent quarters or for the year ending December 31, 2012.

Use of Estimates

The preparation of our Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities. Significant items that are subject to such estimates and assumptions include investment valuation, allowance for doubtful accounts against patient receivables, insurance reserves, income taxes and enhancement accruals. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ significantly from the estimates under different assumptions or conditions.

Reclassifications

We have reclassified certain prior-period amounts in the Condensed Consolidated Balance Sheets and Statements of Cash Flows to conform to current period presentation. The reclassifications were not material to the Condensed Consolidated Financial Statements.

6

LCA-Vision Inc.

Notes to Condensed Consolidated Financial Statements (Unaudited)

Recent Accounting Pronouncements

In June 2011, the Financial Accounting Standards Board (“FASB”) issued new guidance requiring the presentation of other comprehensive income in a statement presented with equal prominence to the other primary financial statements. The new guidance eliminates the current option to report other comprehensive income and its components in the statement of stockholders’ equity and requires one of two alternatives for the presentation of items of net income and other comprehensive income: (1) in a single continuous statement referred to as the statement of comprehensive income, or (2) in two separate, but consecutive statements. Under either alternative, each component of net income and each component of other comprehensive income, together with totals for each, as well as total comprehensive income, would need to be displayed. The new guidance was adopted in the current quarter with retrospective application required. As the new guidance affects only the presentation of other comprehensive income, the current period adoption did not have a material impact on our Condensed Consolidated Financial Statements.

In May 2011, the FASB issued new guidance related to fair value disclosure requirements. The new guidance was effective and adopted in the current period. The new guidance amended certain accounting and disclosure requirements related to fair value measurements. Additional disclosure requirements include: (1) for Level 3 fair value measurements, quantitative information about unobservable inputs used, a description of the valuation processes used by the entity, and a qualitative discussion about the sensitivity of the measurements to changes in the unobservable inputs; (2) for an entity’s use of a nonfinancial asset that is different from the asset’s highest and best use, the reason for the difference; (3) the financial instruments not measured at fair value but for which disclosure of fair value is required, the fair value hierarchy level in which the fair value measurements were determined; and (4) the disclosure of all transfers between Level 1 and Level 2 of the fair value hierarchy. As the new guidance affects only disclosure, the current period adoption did not have a material impact on our Condensed Consolidated Financial Statements.

Patient Receivables and Allowance for Doubtful Accounts

We provide financing to some of our patients, including those who could not otherwise obtain third-party financing. The terms of the financing usually require the patient to pay an up-front fee which is intended to cover some or all of our variable costs, and then generally we deduct the remainder automatically from the patient’s bank account over a period of 12 to 36 months. We have recorded an allowance for doubtful accounts as a best estimate of the amount of probable credit losses from our patient financing program. Each month, we review the allowance and adjust the allowance based upon our own experience with patient financing. We charge off receivables against the allowance for doubtful accounts when it is probable that a receivable will not be recovered. Our policy is to reserve for all patient receivables that remain open past their financial maturity date and to provide reserves for patient receivables prior to the maturity date so as to bring patient receivables, net of reserves, down to the estimated net realizable value based on historical collectability rates, recent default activity and the current credit environment. Receivable balances that remain open past their financial maturity amounted to $145,000 at March 31, 2012.

We maintained an allowance for doubtful accounts on our patient receivables of $1.7 million at March 31, 2012 and December 31, 2011. During the three months ended March 31, 2012, we wrote-off $217,000 of receivables against the allowance for doubtful accounts and recovered $31,000 in receivables previously written off. During the three months ended March 31, 2011, we wrote-off $194,000 of receivables against the allowance for doubtful accounts and recovered $48,000 in receivables previously written off.

2. Investments

Management determines the appropriate classification of securities at the time of purchase and reevaluates such designation as of each balance sheet date. Currently, we classify all securities as available-for-sale. We carry available-for-sale securities at fair value, with temporary unrealized gains and losses, net of tax, reported in accumulated other comprehensive income, a component of stockholders’ investment. The amortized cost of debt securities in this category reflects amortization of premiums and accretion of discounts to maturity computed under the effective interest method. We include this amortization in the caption “Net investment income and other” within the Condensed Consolidated Statements of Operations and Comprehensive Income. We also include in net investment income realized gains and losses and declines in value determined to be other-than-temporary. We base the cost of securities sold upon the specific identification method. We include interest and dividends on securities classified as available-for-sale in net investment income and other.

7

LCA-Vision Inc.

Notes to Condensed Consolidated Financial Statements (Unaudited)

The following table summarizes unrealized gains and losses related to our investments designated as available-for-sale (dollars in thousands):

	March 31, 2012
	Adjusted Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Corporate obligations	$	10,847	$	1	$	—		$	10,848
U.S. Government notes		10,875		1		(4	)		10,872
Certificates of deposit		2,800		—		—			2,800
Auction rate municipal securities		882		—		—			882
Total investments	$	25,404	$	2	$	(4	)	$	25,402

	December 31, 2011
	Adjusted Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Corporate obligations	$	11,260	$	—	$	(1	)	$	11,259
U.S. Government notes		14,049		7		(4	)		14,052
Auction rate municipal securities		893		9		—			902
Total investments	$	26,202	$	16	$	(5	)	$	26,213

The following table shows the net carrying value (amortized cost) and estimated fair value of debt securities at March 31, 2012 by contractual maturity (dollars in thousands). Expected maturities may differ from contractual maturities because the issuers of the securities may have the right or obligation to prepay obligations without prepayment penalties.

	Amortized Cost		Estimated Fair Value
Due in one year or less	$	21,722	$	21,720
Due after one year through three years		—		—
Due after three years		882		882
Total investments	$	22,604	$	22,602

The following table presents gross unrealized losses and fair values for those investments that were in an unrealized loss position as of March 31, 2012 and December 31, 2011, aggregated by investment category and the length of time that individual securities have been in a continuous loss position (dollars in thousands):

	March 31, 2012					December 31, 2011
	Less than 12 Months					Less than 12 Months
	Fair Value		Unrealized Loss			Fair Value		Unrealized Loss
Corporate obligations	$	—	$	—		$	3,810	$	(1	)
U.S. Government notes		6,854		(4	)		6,758		(4	)
	$	6,854	$	(4	)	$	10,568	$	(5	)

We realized gains of $3,000 and no losses on the sale of our debt securities for the three months ended March 31, 2012. We realized gains of $22,000 and losses of $12,000 on the sale of marketable securities for the three months ended March 31, 2011.

8

LCA-Vision Inc.

Notes to Condensed Consolidated Financial Statements (Unaudited)

We recognized unrealized gains of $2,000 and unrealized losses of $4,000 in accumulated other comprehensive income as of March 31, 2012. We recognized unrealized gains of $43,000 and unrealized losses of $43,000 in accumulated other comprehensive income as of March 31, 2011.

Auction Rate Securities

At March 31, 2012 and December 31, 2011, we held $1.1 million par value of various auction rate securities. The assets underlying the auction rate instruments are municipal bonds. Maturity dates for our auction rate municipal securities range from 2030 to 2036. Given the extent of the decline in fair value associated with our auction rate securities, we recognized an other-than-temporary impairment of $11,000, before taxes, during the three months ended March 31, 2012, and no other-than-temporary impairments during the three months ended March 31, 2011. When evaluating investments for other-than-temporary impairment, we review factors such as the length of time and extent to which fair value has been below cost basis, the financial condition of the issuer of the investment securities and any changes thereto, and our intent to sell, or whether it is more-likely-than-not we would be required to sell the investment before recovery of the investment’s amortized cost basis.

As a result of failed auctions, our auction rate instruments are not currently liquid. Due to the continuation of the unstable credit environment, we believe that the recovery period for most of our auction rate instruments will exceed 12 months. Accordingly, we have classified the fair value of the auction rate instruments that have not been redeemed prior to March 31, 2012 as long-term.

3. Fair Values of Financial Instruments

U.S. GAAP establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:

Level 1:  Quoted prices for identical assets or liabilities in active markets at the measurement date

Level 2:  Observable market-based inputs or unobservable inputs that are corroborated by market data at the measurement date

Level 3:  Unobservable inputs reflecting management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date

The fair value hierarchy requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

The following table summarizes fair value measurements by level at March 31, 2012 and December 31, 2011 for assets and liabilities measured at fair value on a recurring basis (dollars in thousands):

	Level 1				Level 2				Level 3				Total
Description	2012		2011		2012		2011		2012		2011		2012		2011
Cash and cash equivalents	$	22,914	$	18,568	$	—	$	—	$	—	$	—	$	22,914	$	18,568
Investments		2,800		—		21,720		25,311		882		902		25,402		26,213
Total assets at fair value	$	25,714	$	18,568	$	21,720	$	25,311	$	882	$	902	$	48,316	$	44,781

Cash and cash equivalents are comprised of either bank deposits or amounts invested in money market funds, the fair value of which is based on quoted market prices. Certificates of deposit have original maturities greater than 90 days and less than one year. The fair values of some investment securities included within our investment portfolio are based on quoted market prices from various bond exchanges. Certain of our debt securities are classified at fair value utilizing Level 2 inputs. For these securities, fair value is measured using observable market data that includes dealer quotes, live trading levels, trade execution data, credit information and the bond’s terms and conditions.

9

LCA-Vision Inc.

Notes to Condensed Consolidated Financial Statements (Unaudited)

The fair values of our auction rate instruments are classified in Level 3 because they are valued using a trinomial discount model as there is insufficient observable auction rate market information available to determine the fair value of these investments. The determination of the fair value of the auction rate instruments employs assumptions including financial standing of the issuer of the instruments, final stated maturities, estimates of the probability of the issue being called prior to final maturity (ranging from 83.1% to 86.8%), estimates of the probability of defaults (ranging from 12.8% to 14.9%) and recoveries (ranging from 40% to 60%), expected changes in interest rates paid on the securities, interest rates paid on similar instruments, and an estimated illiquidity discount (ranging from 4% to 5%) due to extended redemption periods. Significant increases (decreases) in any of those inputs in isolation would result in a significantly lower (higher) fair value measurement. Generally, a change in the assumption used for the probability of default is accompanied by a directionally similar change in the assumption used for the probability of principal returned prior to maturity and the liquidity risk premium.

There were no transfers between Level 1 and Level 2 measurements in the three months ended March 31, 2012 and 2011. The following sets forth a reconciliation of beginning and ending balances for each major category of assets measured at fair value using significant unobservable inputs (Level 3) for the three months ended March 31, 2012 and 2011 (dollars in thousands):

	For the Three Months Ended March 31,
	2012			2011
Balance at beginning of period	$	902		$	951
Losses included in earnings		(11	)		—
(Losses) gains included in other comprehensive income		(9	)		11
Balance as of March 31	$	882		$	962

4. Income Taxes

The following table presents the components of our income tax expense for the following periods (dollars in thousands):

	Three Months Ended March 31,
	2012			2011
Current:
Federal	$	7		$	5
State and local		17			36
Total Current		24			41
Deferred:
Federal	$	—		$	—
State and local		—			—
Total Deferred		—			—
Income tax expense	$	24		$	41
Effective income tax rate		0.6	%		2.0	%

Our effective tax rate for the three-month period ended March 31, 2012 was impacted by a full valuation allowance against all of our deferred tax assets, net of deferred tax liabilities.

10

LCA-Vision Inc.

Notes to Condensed Consolidated Financial Statements (Unaudited)

As of March 31, 2012 and December 31, 2011, deferred tax assets net of deferred tax liabilities totaled $22.0 million and $23.4 million, respectively, offset by full valuation allowances. The gross deferred tax asset and the associated valuation allowance were both reduced by $1.4 million to reflect the utilization of net operating loss carryforwards based on our profit in the first quarter of 2012. Because it is not more-likely-than-not that we will realize our deferred tax assets, we did not record the related tax benefits in the United States and state jurisdictions during the three months ended March 31, 2012. Income tax expense for the three-month periods ended March 31, 2012 and 2011 includes interest on unrecognized tax benefits and state taxes in certain jurisdictions.

During the three-month period ended March 31, 2012, there were no significant changes to the liability for unrecognized tax benefits or potential interest and penalties recorded as a component of income tax. The total amount of unrecognized tax benefits at March 31, 2012 and December 31, 2011 was $610,000 and $614,000, respectively. It is reasonably possible that the amount of the total unrecognized tax benefits may change in the next 12 months. However, we do not believe that any anticipated change will be material to the Condensed Consolidated Financial Statements. In March 2012, the Internal Revenue Service began an audit of the 2010 tax year. Based on the early status of the audit and the protocol of finalizing audits by the relevant authority, it is not possible to estimate the impact of the changes, if any, to the previously recorded liability for unrecognized tax benefits.

5. Earnings Per Common Share

We calculate basic earnings per common share data using the weighted average number of common shares outstanding during the period. Diluted earnings per share data reflects the potential dilution that would occur if common stock equivalents were exercised or converted to common stock but only to the extent that they are considered dilutive to our earnings. The following table is a reconciliation of basic and diluted earnings per share data for the following periods (amounts in thousands, except per share amounts):

	Three Months Ended March 31,
	2012		2011
Basic
Net income	$	3,846	$	2,019
Weighted average shares outstanding		18,895		18,743
Basic earnings per common share	$	0.20	$	0.11
Diluted
Net income	$	3,846	$	2,019
Weighted average shares outstanding		18,895		18,743
Effect of dilutive securities
Stock options		3		6
Restricted stock		192		135
Weighted average common shares and potential dilutive shares		19,090		18,884
Diluted earnings per common share	$	0.20	$	0.11

11

LCA-Vision Inc.

Notes to Condensed Consolidated Financial Statements (Unaudited)

6. Stock-Based Compensation

We have five stock incentive plans through which employees and directors have been or are granted stock-based compensation. We recognize compensation expense for the grant date fair value of stock-based awards over the applicable vesting period. The components of our pre-tax stock-based compensation expense, net of forfeitures, and associated income tax effect were as follows for the following periods (dollars in thousands):

	Three Months Ended March 31,
	2012		2011
Stock options	$	15	$	17
Restricted stock		489		358
		504		375
Income tax effect		195		145
	$	309	$	230

We estimate the fair value of stock options granted using the Black-Scholes option-pricing model. This model requires several assumptions, which we have developed and update based on historical trends and current market observations. The accuracy of these assumptions is critical to the estimate of fair value for these equity instruments.

Our restricted stock unit awards include both time-based awards that vest ratably over three years and restricted stock unit awards that are tied to the achievement of certain financial targets and stock performance criteria that cliff-vest in three years. The financial targets include revenue measurements. Total stockholder return is considered a market condition and the fair value of those awards was calculated using a Monte Carlo simulation valuation model.

7. Restructuring Charges

At March 31, 2012 and December 31, 2011, we included restructuring reserves expected to be paid within the year of $1.3 million for both periods in “Accrued liabilities and other” in the Condensed Consolidated Balance Sheets. Long-term restructuring reserves were $745,000 and $1.0 million at March 31, 2012 and December 31, 2011, respectively, and were included in “Other long-term liabilities.” The decline in restructuring reserves relates primarily to lease payments during the three months ending March 31, 2012. The fair value measurements in all periods utilized market prices of similar assets in determining fair value, which is a Level 3 input under U.S. GAAP.

The following table summarizes the restructuring reserve for the three months ended March 31, 2012 (dollars in thousands):

	Employee Separation Costs			Contract Termination Costs			Total
Balance at December 31, 2011	$	20		$	2,298		$	2,318
Liabilities recognized		—			—			—
Utilized		(20	)		(291	)		(311	)
Balance at March 31, 2012	$	—		$	2,007		$	2,007

8. Debt

Our debt consisted of $3.3 million and $4.0 million related to our bank loan as of March 31, 2012 and December 31, 2011, respectively. Of the total debt obligation, $3.0 million was due within 12 months as of both March 31, 2012 and December 31, 2011.

The carrying value of our long-term debt approximates the estimated fair value as of March 31, 2012.

12

LCA-Vision Inc.

Notes to Condensed Consolidated Financial Statements (Unaudited)

9. Comprehensive Income

The components of accumulated other comprehensive income consisted of the following (dollars in thousands):

	March 31, 2012			December 31, 2011
Foreign currency translation adjustment	$	675		$	572
Unrealized investment (loss) gain		(2	)		11
Accumulated other comprehensive income	$	673		$	583

The components of comprehensive income consisted of the following for the following periods (dollars in thousands):

	Three Months Ended
	March 31,
	2012			2011
Net income	$	3,846		$	2,019
Unrealized investment loss		(13	)		—
Foreign currency translation		103			139
Comprehensive income	$	3,936		$	2,158

10. Commitments and Contingencies

Our business results in a number of medical malpractice lawsuits. We are insured through our captive insurance company to provide coverage for current claims brought against us. We use the captive insurance company for both primary insurance and excess liability coverage. A number of claims are now pending with our captive insurance company.

Third-party actuaries determine our loss reserves based on our historical claim experience, comparable industry experience and recent trends that would impact the ultimate settlement of claims. However, due to the uncertainties inherent in the determination of these liabilities, the ultimate settlement of claims incurred through March 31, 2012 could differ from the amounts recorded. At March 31, 2012 and December 31, 2011, we maintained insurance reserves of $7.1 million and $7.2 million, respectively, of which $939,000 and $951,000 have been classified as current within the caption “Accrued liabilities and other” in the Condensed Consolidated Balance Sheets. Although our insurance reserve reflects our best estimate of the amount of probable loss, we believe the range of loss that is reasonably possible to have been incurred to be approximately $5.6 million to $12.4 million at March 31, 2012. We record any adjustment to these estimates in the period determined.

In addition to the above, we are periodically subject to various other claims and lawsuits. We believe that none of these other claims or lawsuits to which we are currently subject, individually or in the aggregate, will have a material adverse affect on our business, financial condition, results of operations or cash flows.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Information included in this Quarterly Report on Form 10-Q contains forward-looking statements that involve potential risks and uncertainties. Actual results could differ materially from those discussed herein. Factors that could cause or contribute to such differences include, but are not limited to, those discussed herein and those discussed in our Annual Report on Form 10-K for the year ended December 31, 2011. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date thereof.

We file annual, quarterly and current reports, proxy statements and other information with the SEC under the Exchange Act. These reports and other information filed by us may be read and copied at the Public Reference Room of the SEC, 100 F Street N.E., Washington, D.C. 20549. Information may be obtained about the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains a website (www.sec.gov) that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC.

13

This Management’s Discussion and Analysis section provides an overview of our financial condition as of March 31, 2012, and the results of operations for the three months ended March 31, 2012 and 2011. This discussion should be read in conjunction with our Condensed Consolidated Financial Statements and the accompanying Notes, as well as our Annual Report on Form 10-K for the year ended December 31, 2011. Results of interim periods may not be indicative of the results for subsequent periods or the full year.

Overview

Key financial highlights for the three months ended March 31, 2012 include (all comparisons are with the corresponding period of 2011):

• Revenues increased 11.9% to $36.1 million from $32.3 million; adjusted revenues increased 13.9% to $35.3 million from $31.0 million.

• Total procedure volume increased 11.3% to 20,987 procedures from 18,857 procedures.

• Operating income increased to $3.8 million from $2.0 million; adjusted operating income increased to $3.0 million from $838,000. The improvement in operating income and adjusted operating income reflects higher procedure revenue partially offset by increases in variable costs, additional spending on marketing and advertising, and increases in general and administrative costs.

• Marketing cost per eye decreased to $326 from $344.

• Net income was $3.8 million, or $0.20 per share, compared with net income of $2.0 million, or $0.11 per share.

• Net cash provided by operations was $4.5 million compared with $4.8 million. Although net income increased substantially for the first quarter of 2012, changes in working capital resulted in a reduction of cash from operations in the first quarter of 2012 compared with a source of cash in the prior year.

• Cash and investments increased by $3.5 million to $48.3 million as of March 31, 2012, compared with $44.8 million as of December 31, 2011.

We derive substantially all of our revenues from the delivery of laser vision correction procedures performed in our U.S. vision centers. Our revenues, therefore, depend on our volume of procedures and are impacted by a number of factors, including the following:

• Fluctuating economic conditions, consumer confidence and discretionary spending levels,

• Our ability to generate patients through our arrangements with managed care companies, direct-to-consumer advertising and word-of-mouth referrals,

• The availability of patient financing,

• Our ability to manage equipment and operating costs, and

• The impact of competitors and discounting practices in our industry.

Other factors that impact our revenues include:

• Deferred revenue from the sale, prior to June 15, 2007, of separately priced acuity programs, and

• Our mix of procedures among the different types of laser technology.

Because our revenues are primarily a function of the number of laser vision correction procedures performed and the pricing for these services, and many of our costs are fixed, our vision centers have a relatively high degree of operating leverage. As a result, our level of procedure volume can have a significant impact on our level of profitability. The following table details the number of total procedures performed at our consolidated vision centers. Included within total procedure volume are laser vision correction, cataract and implantable collamer lens procedures.

	2012		2011
First quarter		20,987		18,857
Second quarter		—		14,081
Third quarter		—		12,444
Fourth quarter		—		14,205
Year		20,987		59,587

14

As of March 31, 2012, we operated 52 LasikPlus^® fixed-site laser vision centers in the United States. During March 2012, one of our Baltimore, Maryland market vision center’s lease expired, and we elected not to renew. We are finalizing plans to re-open a pre- and post-operative vision center in the same market in the second quarter of 2012.

Economic conditions in the United States have resulted in a continued low consumer confidence level and cautious high-end discretionary spending for many consumers that has continued to impact our procedure volume and operating results. Except for the replacement center in Maryland described above, we have no immediate plans to open new vision centers until we move closer to sustained profitability in our core laser vision correction business.

We have provided both adjusted revenues and operating losses as a means of measuring performance that adjusts for the non-cash impact of accounting for separately priced extended warranties which we offered prior to June 15, 2007. We believe the adjusted information better reflects operating performance and therefore is more meaningful to investors. We provide below a reconciliation of revenues and operating income reported in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) (dollars in thousands).

	Three Months Ended March 31,
	2012			2011
Revenues
Reported U.S. GAAP	$	36,138		$	32,282
Adjustments
Amortization of prior deferred revenue		(821	)		(1,269	)
Adjusted revenues	$	35,317		$	31,013
Operating Income
Reported U.S. GAAP	$	3,754		$	1,980
Adjustments
Amortization of prior deferred revenue		(821	)		(1,269	)
Amortization of prior professional fees		82			127
Adjusted operating income	$	3,015		$	838

Revenues

In the first quarter of 2012, revenues increased by $3.9 million, or 11.9%, to $36.1 million from $32.3 million in the first quarter of 2011. Procedure volume increased 11.3% to 20,987 in the first quarter of 2012 from 18,857 in the first quarter of 2011. The adjusted average reported revenue per procedure, which excludes the impact of deferring revenue from separately priced extended warranties, increased to $1,683 in the first quarter of 2012 from $1,645 in the first quarter of 2011. The components of the revenue change include (dollars in thousands):

Increase in revenue from higher procedure volume	$	3,509
Impact from increase in average selling price, adjusted for revenue deferral		795
Change in deferred revenue		(448	)
Increase in revenues	$	3,856

Operating costs and expenses

Our operating costs and expenses include:

• Medical professional and license fees, including per procedure fees for the ophthalmologists performing laser vision correction, and per procedure license fees paid to certain equipment suppliers of our excimer and femtosecond lasers,

• Direct costs of services, including the salary component of physician compensation for certain physicians employed by us, staff compensation, facility costs of operating laser vision correction centers, equipment lease and maintenance costs, medical malpractice insurance costs, surgical supplies, financing charges for third-party patient financing, and other costs related to revenues,

• General and administrative costs, including corporate headquarters and call center staff expense and other overhead costs,

• Marketing and advertising costs, and

• Depreciation of equipment and leasehold improvements.

15

Medical professional and license fees

Medical professional and license fees in the first quarter of 2012, totaling $8.7 million, increased by $699,000, or 8.8%, from the first quarter of 2011. The increase was primarily due to higher physician fees of $406,000 and license fees of $354,000 associated with increased procedure volume, partially offset by a decrease in our enhancement costs related to previously closed vision centers. The amortization of the deferred medical professional fees attributable to prior years was $82,000 in the first quarter of 2012 compared to $127,000 in the first quarter of 2011.

Direct costs of services

Direct costs of services increased $891,000, or 8.1%, in the first quarter of 2012 to $11.9 million from $11.0 million in the first quarter of 2011. The increase was due primarily to salaries, incentives and benefits, laser maintenance fees, finance fees, insurance and supply costs in order to accommodate increased procedure volume. Partially offsetting the increases was a decrease in rent expense from recent favorable renegotiations of leases.

General and administrative

General and administrative expenses increased in the first quarter of 2012 by $250,000, or 7.2%, from the first quarter of 2011, due primarily to increased salaries and incentives, stock-based compensation and professional fees.

Marketing and advertising

Marketing and advertising expenses in the first quarter of 2012 increased by $355,000, or 5.5%, from the first quarter of 2011. These expenses were 19.0% of revenues in the first quarter of 2012 compared to 20.1% during the first quarter of 2011. We reduced marketing cost per eye to $326 for the first quarter of 2012 from $344 in the same period of 2011. We adjust our marketing spend levels continuously in an attempt to align spending levels with consumer demand. We are continuing to work to develop more efficient marketing techniques and expand local initiatives as a means to attract patients. The first quarter marketing cost per eye is typically lower compared with other quarters due to the seasonality of procedure volume from patients utilizing their flexible spending accounts during the first quarter. Our future operating profitability will depend in large part on the success of our efforts in this regard.

Depreciation

Depreciation expense decreased in the first quarter of 2012 by $142,000, or 9.8%, to $1.3 million from $1.5 million in the first quarter of 2011. Due to reduced capital expenditures beginning in 2009 and impairment charges and disposals as a result of closed vision centers in 2009 and 2010, our depreciable base of assets has decreased.

Restructuring charges

There were no restructuring charges in the first quarter of 2012, compared to $56,000 in the first quarter of 2011. Charges for 2011 related primarily to adjustments to previous estimates for contract termination costs for closed vision centers and additional severance costs.

Gain on sale of assets

We sold one laser and other assets held for sale for a gain of approximately $78,000 in the three months ended March 31, 2012. Gain on sale of assets was $163,000 in the three months ended March 31, 2011.

Non-operating income and expenses

Net investment income and other in the first quarter of 2012 increased by $36,000 to $116,000, primarily due to a reduction in interest expense as a result of our lower debt balance in 2012.

Income taxes

Income tax expense for the three months ended March 31, 2012 and 2011 includes the interest on unrecognized tax benefits and state taxes in certain jurisdictions.

16

Liquidity and Capital Resources

At March 31, 2012, we held $47.4 million in cash and cash equivalents and short-term investments, an increase of $3.5 million from $43.9 million at December 31, 2011. Our cash flows from operating, investing, and financing activities, as reflected in the Condensed Consolidated Statements of Cash Flows, are summarized as follows (dollars in thousands):

	Three Months Ended
	March 31,
	2012			2011
Cash provided by (used in):
Operating activities	$	4,493		$	4,815
Investing activities		786			2,150
Financing activities		(1,036	)		(1,244	)
Net effect of exchange rate changes on cash and cash equivalents		103			131
Net increase in cash and cash equivalents	$	4,346		$	5,852

Cash flows generated from operating activities amounted to $4.5 million for the three months ended March 31, 2012 compared to $4.8 million for the same period in 2011. Although earnings increased in 2012, working capital changes reduced the cash from operations in 2012 but were a source of cash in 2011. The working capital changes resulted primarily from changes in accounts receivable related to patient financing and merchant card banking, and changes in accounts payable, accruals and prepaid expenses related to revised vender terms and new vendors. At March 31, 2012, working capital (excluding debt due within one year) amounted to $33.3 million compared to $29.7 million at December 31, 2011. Liquid assets (cash and cash equivalents, short-term investments, and accounts receivable) amounted to 199.2% of current liabilities at March 31, 2012, compared to 187.1% at December 31, 2011.

We continue to offer our own sponsored patient financing. As of March 31, 2012, we had $4.0 million in patient receivables, net of allowance for doubtful accounts, which was an increase of $859,000 or 27.4% from December 31, 2011. We continually monitor the allowance for doubtful accounts and will adjust our lending criteria or require greater down payments if our experience indicates that is necessary. However, our ability to collect patient accounts depends, in part, on overall economic conditions. Bad debt expense was approximately 1.0% of revenue for the three months ended March 31, 2012 and 2011.

During the three months ended March 31, 2012, we purchased $32.2 million of investment securities and received proceeds from the sale of investment securities of $32.9 million. Our investment portfolio consists of high-grade commercial paper and government securities with maturities typically ranging from 30 to 90 days. The ongoing maturities and reinvestment result in the high level of purchasing and selling activity reflected in the Condensed Consolidated Statements of Cash Flows.

Our outstanding debt balance was $3.3 million at March 31, 2012. Our loan agreement contains no financial covenants and is secured by certain medical equipment. Loan repayments of $731,000 for the three months ended March 31, 2012 reflect a decrease of $248,000, compared to the same period in 2011, due primarily to payoffs of femtosecond lasers sold in 2011.

At both March 31, 2012 and December 31, 2011, we held $1.1 million par value of various auction rate securities. The assets underlying the auction rate instruments are municipal bonds. Our auction rate instruments are not currently liquid. Maturity dates for our auction rate securities range from 2030 to 2036. In the first quarter of 2011, $1.1 million was redeemed for $891,000. The redemption value was equal to the securities carrying value at the time of liquidation. In the first quarter of 2012, there were no securities redeemed. See Note 2 to Condensed Consolidated Financial Statements for further information regarding our auction rate security investments.

We have not opened any new vision centers in 2012 or 2011. Capital expenditures for the three months ended March 31, 2012 and 2011 were $67,000 and $634,000, respectively. The 2012 expenditures related primarily to costs to purchase cataract equipment as part of our business expansion initiative.

We affirm that the number of procedures companywide required for our laser vision correction business to achieve breakeven cash flow, after capital expenditures and debt service, remains approximately 70,000 per year. We expect to incur start-up losses and capital investment during the expansion phase for our cataract and IOL business.

17

Critical Accounting Estimates

There have been no material changes in the critical accounting policies described in Management’s Discussion and Analysis in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

The carrying values of financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, approximate fair value because of the short maturity of these instruments.

We record short-term investments at fair value. Due to the short-term nature of the investments in corporate bonds, municipal and U.S. Government bonds, we believe there is little risk to the valuation of these debt securities.

Long-term investments include auction rate securities that are currently failing auction. These investments are recorded at fair value using a trinomial discount model. We are divesting all auction rate securities as the market allows. There can be no assurance, however, that the issuers of the auction rate securities that we hold will do so in advance of their maturity or the restoration of a regularized auction market.

We have a low exposure to changes in foreign currency exchange rates and, as such, have not used derivative financial instruments to manage foreign currency fluctuation risk.

In addition, because our secured indebtedness is at a fixed rate, we have limited interest rate risk.

Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

Under the supervision of and with the participation of our management, including the company’s Chief Operating Officer (COO) and Chief Financial Officer (CFO), an evaluation of the effectiveness of our disclosure controls and procedures was performed as of March 31, 2012. Based on this evaluation, the COO and CFO concluded that our disclosure controls and procedures are effective to ensure that material information is (1) accumulated and communicated to our management as appropriate to allow timely decisions regarding disclosure and (2) recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission.

(b) Changes in Internal Control over Financial Reporting

Under the supervision of and with the participation of our management, including the COO and CFO, an evaluation of our internal control over financial reporting was performed as of March 31, 2012. Based on this evaluation, management concluded that there were no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2012 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

Not applicable.

Item 1A. Risk Factors

For a discussion of the risk factors attributable to our business, refer to Part I, Item 1A., “Risk Factors,” contained in our Annual Report on Form 10-K for the year ended December 31, 2011. There have been no material changes to the risk factors disclosed in the Annual Report.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Not applicable.

18

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Not applicable.

Item 6. Exhibits

Exhibits Number	Description
31.1	COO Certification under Section 302 of the Sarbanes-Oxley Act of 2002
31.2	CFO Certification under Section 302 of the Sarbanes-Oxley Act of 2002
32	Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
*101.INS	XBRL Instance Document
*101.SCH	XBRL Taxonomy Extension Schema Document
*101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
*101.LAB	XBRL Taxonomy Extension Label Linkbase Document
*101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

* Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

19

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	LCA-VISION INC.
Date: April 26, 2012	/s/ David L. Thomas
	David L. Thomas
	Chief Operating Officer
Date: April 26, 2012	/s/ Michael J. Celebrezze
	Michael J. Celebrezze
	Senior Vice President of Finance, Chief Financial Officer and Treasurer

20

EX-31.1

Exhibit 31.1

Certification of Chief Operating Officer

I, David L. Thomas, certify that:

1. I have reviewed this report on Form 10-Q of LCA-Vision Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: April 26, 2012	/s/ David L. Thomas
	David L. Thomas
	Chief Operating Officer

EX-31.2

Exhibit 31.2

Certification of Chief Financial Officer

I, Michael J. Celebrezze, certify that:

1. I have reviewed this report on Form 10-Q of LCA-Vision Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: April 26, 2012	/s/ Michael J. Celebrezze
	Michael J. Celebrezze
	Senior Vice President of Finance, Chief Financial Officer and Treasurer

EX-32

Exhibit 32

CERTIFICATIONS PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of LCA-Vision Inc. (the “Company”), does hereby certify, to such officer’s knowledge, that:

This quarterly report on Form 10-Q for the period ended March 31, 2012 of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in this Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: April 26, 2012	/s/ David L. Thomas
	David L. Thomas
	Chief Operating Officer

Date: April 26, 2012	/s/ Michael J. Celebrezze
	Michael J. Celebrezze
	Senior Vice President of Finance, Chief Financial Officer and Treasurer

XML

Income Taxes

3 Months Ended

Mar. 31, 2012

Income Taxes [Abstract]

Income Taxes

4. Income Taxes

The following table presents the components of our income tax expense for the following periods (dollars in thousands):

	Three Months Ended March 31,
	2012			2011
Current:
Federal	$	7		$	5
State and local		17			36
Total Current		24			41
Deferred:
Federal	$	—		$	—
State and local		—			—
Total Deferred		—			—
Income tax expense	$	24		$	41
Effective income tax rate		0.6	%		2.0	%

Our effective tax rate for the three-month period ended March 31, 2012 was impacted by a full valuation allowance against all of our deferred tax assets, net of deferred tax liabilities.

As of March 31, 2012 and December 31, 2011, deferred tax assets net of deferred tax liabilities totaled $22.0 million and $23.4 million, respectively, offset by full valuation allowances. The gross deferred tax asset and the associated valuation allowance were both reduced by $1.4 million to reflect the utilization of net operating loss carryforwards based on our profit in the first quarter of 2012. Because it is not more-likely-than-not that we will realize our deferred tax assets, we did not record the related tax benefits in the United States and state jurisdictions during the three months ended March 31, 2012. Income tax expense for the three-month periods ended March 31, 2012 and 2011 includes interest on unrecognized tax benefits and state taxes in certain jurisdictions.

During the three-month period ended March 31, 2012, there were no significant changes to the liability for unrecognized tax benefits or potential interest and penalties recorded as a component of income tax. The total amount of unrecognized tax benefits at March 31, 2012 and December 31, 2011 was $610,000 and $614,000, respectively. It is reasonably possible that the amount of the total unrecognized tax benefits may change in the next 12 months. However, we do not believe that any anticipated change will be material to the Condensed Consolidated Financial Statements. In March 2012, the Internal Revenue Service began an audit of the 2010 tax year. Based on the early status of the audit and the protocol of finalizing audits by the relevant authority, it is not possible to estimate the impact of the changes, if any, to the previously recorded liability for unrecognized tax benefits.

XML

Fair Values Of Financial Instruments

3 Months Ended

Mar. 31, 2012

Fair Values Of Financial Instruments [Abstract]

Fair Values Of Financial Instruments

3. Fair Values of Financial Instruments

U.S. GAAP establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:

Level 1:  Quoted prices for identical assets or liabilities in active markets at the measurement date

Level 2:  Observable market-based inputs or unobservable inputs that are corroborated by market data at the measurement date

Level 3:  Unobservable inputs reflecting management's best estimate of what market participants would use in pricing the asset or liability at the measurement date

The fair value hierarchy requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

The following table summarizes fair value measurements by level at March 31, 2012 and December 31, 2011 for assets and liabilities measured at fair value on a recurring basis (dollars in thousands):

	Level 1				Level 2				Level 3				Total
Description	2012		2011		2012		2011		2012		2011		2012		2011
Cash and cash equivalents	$	22,914	$	18,568	$	—	$	—	$	—	$	—	$	22,914	$	18,568
Investments		2,800		—		21,720		25,311		882		902		25,402		26,213
Total assets at fair value	$	25,714	$	18,568	$	21,720	$	25,311	$	882	$	902	$	48,316	$	44,781

Cash and cash equivalents are comprised of either bank deposits or amounts invested in money market funds, the fair value of which is based on quoted market prices. Certificates of deposit have original maturities greater than 90 days and less than one year. The fair values of some investment securities included within our investment portfolio are based on quoted market prices from various bond exchanges. Certain of our debt securities are classified at fair value utilizing Level 2 inputs. For these securities, fair value is measured using observable market data that includes dealer quotes, live trading levels, trade execution data, credit information and the bond's terms and conditions.

The fair values of our auction rate instruments are classified in Level 3 because they are valued using a trinomial discount model as there is insufficient observable auction rate market information available to determine the fair value of these investments. The determination of the fair value of the auction rate instruments employs assumptions including financial standing of the issuer of the instruments, final stated maturities, estimates of the probability of the issue being called prior to final maturity (ranging from 83.1% to 86.8%), estimates of the probability of defaults (ranging from 12.8% to 14.9%) and recoveries (ranging from 40% to 60%), expected changes in interest rates paid on the securities, interest rates paid on similar instruments, and an estimated illiquidity discount (ranging from 4% to 5%) due to extended redemption periods. Significant increases (decreases) in any of those inputs in isolation would result in a significantly lower (higher) fair value measurement. Generally, a change in the assumption used for the probability of default is accompanied by a directionally similar change in the assumption used for the probability of principal returned prior to maturity and the liquidity risk premium.

There were no transfers between Level 1 and Level 2 measurements in the three months ended March 31, 2012 and 2011. The following sets forth a reconciliation of beginning and ending balances for each major category of assets measured at fair value using significant unobservable inputs (Level 3) for the three months ended March 31, 2012 and 2011 (dollars in thousands):

	For the Three Months Ended March 31,
	2012			2011
Balance at beginning of period	$	902		$	951
Losses included in earnings		(11	)		—
(Losses) gains included in other comprehensive income		(9	)		11
Balance as of March 31	$	882		$	962

XML

Condensed Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Mar. 31, 2012	Dec. 31, 2011
Assets
Cash and cash equivalents	$ 22,914	$ 18,568
Short-term investments	24,520	25,311
Patient receivables, net of allowances of $1,002 and $1,035	2,895	2,366
Other accounts receivable, net	2,945	1,974
Prepaid expenses and other	3,714	4,254
Total current assets	56,988	52,473
Property and equipment, net	9,389	10,637
Long-term investments	882	902
Patient receivables, net of allowances of $719 and $634	1,099	769
Other assets	1,349	1,652
Total assets	69,707	66,433
Liabilities and Stockholders' Investment
Accounts payable	9,534	8,103
Accrued liabilities and other	12,129	12,175
Deferred revenue	2,064	2,516
Debt obligations maturing within one year	3,015	2,978
Total current liabilities	26,742	25,772
Long-term insurance reserves, less current portion	6,183	6,264
Long-term debt obligations, less current portion	258	1,026
Other long-term liabilities	6,124	7,106
Stockholders' investment
Common stock ($.001 par value; 25,291,637 shares issued and 18,972,134 and 18,858,147 shares outstanding, respectively)	25	25
Contributed capital	177,790	177,287
Common stock in treasury, at cost (6,319,503 shares and 6,433,490 shares, respectively)	(112,047)	(112,910)
Accumulated deficit	(36,041)	(38,720)
Accumulated other comprehensive income	673	583
Total stockholders' investment	30,400	26,265
Total liabilities and stockholders' investment	$ 69,707	$ 66,433

XML

Description Of Business And Accounting Policies

3 Months Ended

Mar. 31, 2012

Description Of Business And Accounting Policies [Abstract]

Description Of Business And Accounting Policies

1. Description of Business and Accounting Policies

Description of Business

We are a provider of fixed-site laser vision correction services at our LasikPlus^® vision centers. Our vision centers provide the staff, facilities, equipment and support services for performing laser vision correction that employ advanced laser technologies to help correct nearsightedness, farsightedness and astigmatism. We currently use two suppliers for fixed-site excimer lasers: Abbott Medical Optics and Alcon, Inc. Our vision centers are supported by independent ophthalmologists and credentialed optometrists, as well as other healthcare professionals. The ophthalmologists perform the laser vision correction procedures in our vision centers, and ophthalmologists or optometrists conduct pre-procedure evaluations and post-operative follow-up care in-center. Most of our patients currently receive a procedure called Laser-Assisted In Situ Keratomileusis ("LASIK"), which we began performing in the United States in 1996.

As of March 31, 2012, we operated 52 LasikPlus^® fixed-site laser vision centers in the United States. During March 2012, one of our Baltimore, Maryland market vision center's lease expired, and we elected not to renew. We are finalizing plans to re-open a pre- and post-operative vision center in the same market in the second quarter of 2012. Included in the 52 vision centers are two vision centers which we licensed to ophthalmologists to operate using our trademarks. Beginning in 2011, we began offering cataract, premium intraocular lens ("IOL") and implantable collamer lens ("ICL") services in certain of our existing markets under our new Visium Eye Institute^TM brand. Due to the nature of our operations and organization, we operate in only one business segment.

Basis of Presentation

Our Condensed Consolidated Financial Statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") and, in the opinion of management, include all adjustments necessary for a fair presentation of our financial position, results of operations and cash flows for each period presented. These adjustments are of a normal and recurring nature unless otherwise disclosed herein. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") have been condensed or omitted pursuant to SEC rules and regulations.

We derived the Condensed Consolidated Balance Sheet as of December 31, 2011 from audited financial statements but did not include all disclosures required by U.S. GAAP. These Condensed Consolidated Financial Statements should be read in conjunction with our 2011 Annual Report on Form 10-K. Operating results for the three-month period ended March 31, 2012 are not necessarily indicative of the results expected in subsequent quarters or for the year ending December 31, 2012.

Use of Estimates

The preparation of our Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities. Significant items that are subject to such estimates and assumptions include investment valuation, allowance for doubtful accounts against patient receivables, insurance reserves, income taxes and enhancement accruals. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ significantly from the estimates under different assumptions or conditions.

Reclassifications

We have reclassified certain prior-period amounts in the Condensed Consolidated Balance Sheets and Statements of Cash Flows to conform to current period presentation. The reclassifications were not material to the Condensed Consolidated Financial Statements.

Recent Accounting Pronouncements

In June 2011, the Financial Accounting Standards Board ("FASB") issued new guidance requiring the presentation of other comprehensive income in a statement presented with equal prominence to the other primary financial statements. The new guidance eliminates the current option to report other comprehensive income and its components in the statement of stockholders' equity and requires one of two alternatives for the presentation of items of net income and other comprehensive income: (1) in a single continuous statement referred to as the statement of comprehensive income, or (2) in two separate, but consecutive statements. Under either alternative, each component of net income and each component of other comprehensive income, together with totals for each, as well as total comprehensive income, would need to be displayed. The new guidance was adopted in the current quarter with retrospective application required. As the new guidance affects only the presentation of other comprehensive income, the current period adoption did not have a material impact on our Condensed Consolidated Financial Statements.

In May 2011, the FASB issued new guidance related to fair value disclosure requirements. The new guidance was effective and adopted in the current period. The new guidance amended certain accounting and disclosure requirements related to fair value measurements. Additional disclosure requirements include: (1) for Level 3 fair value measurements, quantitative information about unobservable inputs used, a description of the valuation processes used by the entity, and a qualitative discussion about the sensitivity of the measurements to changes in the unobservable inputs; (2) for an entity's use of a nonfinancial asset that is different from the asset's highest and best use, the reason for the difference; (3) the financial instruments not measured at fair value but for which disclosure of fair value is required, the fair value hierarchy level in which the fair value measurements were determined; and (4) the disclosure of all transfers between Level 1 and Level 2 of the fair value hierarchy. As the new guidance affects only disclosure, the current period adoption did not have a material impact on our Condensed Consolidated Financial Statements.

Patient Receivables and Allowance for Doubtful Accounts

We provide financing to some of our patients, including those who could not otherwise obtain third-party financing. The terms of the financing usually require the patient to pay an up-front fee which is intended to cover some or all of our variable costs, and then generally we deduct the remainder automatically from the patient's bank account over a period of 12 to 36 months. We have recorded an allowance for doubtful accounts as a best estimate of the amount of probable credit losses from our patient financing program. Each month, we review the allowance and adjust the allowance based upon our own experience with patient financing. We charge off receivables against the allowance for doubtful accounts when it is probable that a receivable will not be recovered. Our policy is to reserve for all patient receivables that remain open past their financial maturity date and to provide reserves for patient receivables prior to the maturity date so as to bring patient receivables, net of reserves, down to the estimated net realizable value based on historical collectability rates, recent default activity and the current credit environment. Receivable balances that remain open past their financial maturity amounted to $145,000 at March 31, 2012.

We maintained an allowance for doubtful accounts on our patient receivables of $1.7 million at March 31, 2012 and December 31, 2011. During the three months ended March 31, 2012, we wrote-off $217,000 of receivables against the allowance for doubtful accounts and recovered $31,000 in receivables previously written off. During the three months ended March 31, 2011, we wrote-off $194,000 of receivables against the allowance for doubtful accounts and recovered $48,000 in receivables previously written off.

XML

Investments

3 Months Ended

Mar. 31, 2012

Investments [Abstract]

Investments

2. Investments

Management determines the appropriate classification of securities at the time of purchase and reevaluates such designation as of each balance sheet date. Currently, we classify all securities as available-for-sale. We carry available-for-sale securities at fair value, with temporary unrealized gains and losses, net of tax, reported in accumulated other comprehensive income, a component of stockholders' investment. The amortized cost of debt securities in this category reflects amortization of premiums and accretion of discounts to maturity computed under the effective interest method. We include this amortization in the caption "Net investment income and other" within the Condensed Consolidated Statements of Operations and Comprehensive Income. We also include in net investment income realized gains and losses and declines in value determined to be other-than-temporary. We base the cost of securities sold upon the specific identification method. We include interest and dividends on securities classified as available-for-sale in net investment income and other.

The following table summarizes unrealized gains and losses related to our investments designated as available-for-sale (dollars in thousands):

	March 31, 2012
	Adjusted Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Corporate obligations	$	10,847	$	1	$	—		$	10,848
U.S. Government notes		10,875		1		(4	)		10,872
Certificates of deposit		2,800		—		—			2,800
Auction rate municipal securities		882		—		—			882
Total investments	$	25,404	$	2	$	(4	)	$	25,402

	December 31, 2011
	Adjusted Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Corporate obligations	$	11,260	$	—	$	(1	)	$	11,259
U.S. Government notes		14,049		7		(4	)		14,052
Auction rate municipal securities		893		9		—			902
Total investments	$	26,202	$	16	$	(5	)	$	26,213

The following table shows the net carrying value (amortized cost) and estimated fair value of debt securities at March 31, 2012 by contractual maturity (dollars in thousands). Expected maturities may differ from contractual maturities because the issuers of the securities may have the right or obligation to prepay obligations without prepayment penalties.

	Amortized Cost		Estimated Fair Value
Due in one year or less	$	21,722	$	21,720
Due after one year through three years		—		—
Due after three years		882		882
Total investments	$	22,604	$	22,602

The following table presents gross unrealized losses and fair values for those investments that were in an unrealized loss position as of March 31, 2012 and December 31, 2011, aggregated by investment category and the length of time that individual securities have been in a continuous loss position (dollars in thousands):

	March 31, 2012					December 31, 2011
	Less than 12 Months					Less than 12 Months
	Fair Value		Unrealized Loss			Fair Value		Unrealized Loss
Corporate obligations	$	—	$	—		$	3,810	$	(1	)
U.S. Government notes		6,854		(4	)		6,758		(4	)
	$	6,854	$	(4	)	$	10,568	$	(5	)

We realized gains of $3,000 and no losses on the sale of our debt securities for the three months ended March 31, 2012. We realized gains of $22,000 and losses of $12,000 on the sale of marketable securities for the three months ended March 31, 2011.

We recognized unrealized gains of $2,000 and unrealized losses of $4,000 in accumulated other comprehensive income as of March 31, 2012. We recognized unrealized gains of $43,000 and unrealized losses of $43,000 in accumulated other comprehensive income as of March 31, 2011.

Auction Rate Securities

At March 31, 2012 and December 31, 2011, we held $1.1 million par value of various auction rate securities. The assets underlying the auction rate instruments are municipal bonds. Maturity dates for our auction rate municipal securities range from 2030 to 2036. Given the extent of the decline in fair value associated with our auction rate securities, we recognized an other-than-temporary impairment of $11,000, before taxes, during the three months ended March 31, 2012, and no other-than-temporary impairments during the three months ended March 31, 2011. When evaluating investments for other-than-temporary impairment, we review factors such as the length of time and extent to which fair value has been below cost basis, the financial condition of the issuer of the investment securities and any changes thereto, and our intent to sell, or whether it is more-likely-than-not we would be required to sell the investment before recovery of the investment's amortized cost basis.

As a result of failed auctions, our auction rate instruments are not currently liquid. Due to the continuation of the unstable credit environment, we believe that the recovery period for most of our auction rate instruments will exceed 12 months. Accordingly, we have classified the fair value of the auction rate instruments that have not been redeemed prior to March 31, 2012 as long-term.

XML

Condensed Consolidated Balance Sheets (Parenthetical) (USD $) In Thousands, except Share data, unless otherwise specified	Mar. 31, 2012	Dec. 31, 2011
Condensed Consolidated Balance Sheets [Abstract]
Allowances for patient receivables, current	$ 1,002	$ 1,035
Allowances for patient receivables, non-current	$ 719	$ 634
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares issued	25,291,637	25,291,637
Common stock, shares outstanding	18,972,134	18,858,147
Treasury stock, shares	6,319,503	6,433,490

XML

Document And Entity Information	3 Months Ended
	Mar. 31, 2012	Apr. 19, 2012
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2012
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q1
Entity Registrant Name	LCA VISION INC
Entity Central Index Key	0001003130
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		18,972,134

XML

Condensed Consolidated Statements Of Operations And Comprehensive Income (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2012	Mar. 31, 2011
Condensed Consolidated Statements Of Operations And Comprehensive Income [Abstract]
Revenues	$ 36,138	$ 32,282
Operating costs and expenses
Medical professional and license fees	8,682	7,983
Direct costs of services	11,911	11,020
General and administrative expenses	3,706	3,456
Marketing and advertising	6,851	6,496
Depreciation	1,312	1,454
Restructuring charges		56
Total operating cost	32,462	30,465
Gain on sale of assets	78	163
Operating income	3,754	1,980
Net investment income and other	116	80
Income before taxes	3,870	2,060
Income tax expense	24	41
Net income	3,846	2,019
Earnings per common share
Basic	$ 0.20	$ 0.11
Diluted	$ 0.20	$ 0.11
Weighted average shares outstanding
Basic	18,895	18,743
Diluted	19,090	18,884
Comprehensive income	$ 3,936	$ 2,158

XML

Restructuring Charges

3 Months Ended

Mar. 31, 2012

Restructuring Charges [Abstract]

Restructuring Charges

7. Restructuring Charges

At March 31, 2012 and December 31, 2011, we included restructuring reserves expected to be paid within the year of $1.3 million for both periods in "Accrued liabilities and other" in the Condensed Consolidated Balance Sheets. Long-term restructuring reserves were $745,000 and $1.0 million at March 31, 2012 and December 31, 2011, respectively, and were included in "Other long-term liabilities." The decline in restructuring reserves relates primarily to lease payments during the three months ending March 31, 2012. The fair value measurements in all periods utilized market prices of similar assets in determining fair value, which is a Level 3 input under U.S. GAAP.

The following table summarizes the restructuring reserve for the three months ended March 31, 2012 (dollars in thousands):

	Employee Separation Costs			Contract Termination Costs			Total
Balance at December 31, 2011	$	20		$	2,298		$	2,318
Liabilities recognized		—			—			—
Utilized		(20	)		(291	)		(311	)
Balance at March 31, 2012	$	—		$	2,007		$	2,007

XML

Stock-Based Compensation

3 Months Ended

Mar. 31, 2012

Stock-Based Compensation [Abstract]

Stock-Based Compensation

6. Stock-Based Compensation

We have five stock incentive plans through which employees and directors have been or are granted stock-based compensation. We recognize compensation expense for the grant date fair value of stock-based awards over the applicable vesting period. The components of our pre-tax stock-based compensation expense, net of forfeitures, and associated income tax effect were as follows for the following periods (dollars in thousands):

	Three Months Ended March 31,
	2012		2011
Stock options	$	15	$	17
Restricted stock		489		358
		504		375
Income tax effect		195		145
	$	309	$	230

We estimate the fair value of stock options granted using the Black-Scholes option-pricing model. This model requires several assumptions, which we have developed and update based on historical trends and current market observations. The accuracy of these assumptions is critical to the estimate of fair value for these equity instruments.

Our restricted stock unit awards include both time-based awards that vest ratably over three years and restricted stock unit awards that are tied to the achievement of certain financial targets and stock performance criteria that cliff-vest in three years. The financial targets include revenue measurements. Total stockholder return is considered a market condition and the fair value of those awards was calculated using a Monte Carlo simulation valuation model.

XML

Commitments And Contingencies

3 Months Ended

Mar. 31, 2012

Commitments And Contingencies [Abstract]

Commitments And Contingencies

10. Commitments and Contingencies

Our business results in a number of medical malpractice lawsuits. We are insured through our captive insurance company to provide coverage for current claims brought against us. We use the captive insurance company for both primary insurance and excess liability coverage. A number of claims are now pending with our captive insurance company.

Third-party actuaries determine our loss reserves based on our historical claim experience, comparable industry experience and recent trends that would impact the ultimate settlement of claims. However, due to the uncertainties inherent in the determination of these liabilities, the ultimate settlement of claims incurred through March 31, 2012 could differ from the amounts recorded. At March 31, 2012 and December 31, 2011, we maintained insurance reserves of $7.1 million and $7.2 million, respectively, of which $939,000 and $951,000 have been classified as current within the caption "Accrued liabilities and other" in the Condensed Consolidated Balance Sheets. Although our insurance reserve reflects our best estimate of the amount of probable loss, we believe the range of loss that is reasonably possible to have been incurred to be approximately $5.6 million to $12.4 million at March 31, 2012. We record any adjustment to these estimates in the period determined.

In addition to the above, we are periodically subject to various other claims and lawsuits. We believe that none of these other claims or lawsuits to which we are currently subject, individually or in the aggregate, will have a material adverse affect on our business, financial condition, results of operations or cash flows.

XML

Debt

3 Months Ended

Mar. 31, 2012

Debt [Abstract]

Debt

8. Debt

Our debt consisted of $3.3 million and $4.0 million related to our bank loan as of March 31, 2012 and December 31, 2011, respectively. Of the total debt obligation, $3.0 million was due within 12 months as of both March 31, 2012 and December 31, 2011.

The carrying value of our long-term debt approximates the estimated fair value as of March 31, 2012.

XML

Comprehensive Income

3 Months Ended

Mar. 31, 2012

Comprehensive Income [Abstract]

Comprehensive Income

9. Comprehensive Income

The components of accumulated other comprehensive income consisted of the following (dollars in thousands):

	March 31, 2012			December 31, 2011
Foreign currency translation adjustment	$	675		$	572
Unrealized investment (loss) gain		(2	)		11
Accumulated other comprehensive income	$	673		$	583

The components of comprehensive income consisted of the following for the following periods (dollars in thousands):

	Three Months Ended
	March 31,
	2012			2011
Net income	$	3,846		$	2,019
Unrealized investment loss		(13	)		—
Foreign currency translation		103			139
Comprehensive income	$	3,936		$	2,158

XML

Condensed Consolidated Statements Of Cash Flows (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2012	Mar. 31, 2011
Cash flows from operating activities:
Net income	$ 3,846	$ 2,019
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	1,312	1,454
Provision for loss on doubtful accounts	243	155
Loss (gain) on sale of investments, net	8	(10)
Gain on sale of property and equipment	(78)	(163)
Stock-based compensation	504	375
Insurance reserves	(93)	(205)
Changes in operating assets and liabilities:
Patient accounts receivable	(1,097)	(290)
Other accounts receivable	(975)	(370)
Prepaid expenses and other	449	1,406
Accounts payable	1,431	535
Deferred revenue, net of professional fees	(738)	(1,142)
Accrued liabilities and other	(319)	1,051
Net cash provided by operations	4,493	4,815
Cash flows from investing activities:
Purchases of property and equipment	(67)	(634)
Proceeds from sale of assets	127	570
Purchases of investment securities	(32,203)	(40,061)
Proceeds from sale of investment securities	32,929	42,267
Other, net		8
Net cash provided by investing activities	786	2,150
Cash flows from financing activities:
Principal payments of loan	(731)	(979)
Shares repurchased for treasury stock	(357)	(288)
Proceeds from exercise of stock options	52	23
Net cash used in financing activities	(1,036)	(1,244)
Net effect of exchange rate changes on cash and cash equivalents	103	131
Increase in cash and cash equivalents	4,346	5,852
Cash and cash equivalents at beginning of period	18,568	19,350
Cash and cash equivalents at end of period	$ 22,914	$ 25,202

XML

Earnings Per Common Share

3 Months Ended

Mar. 31, 2012

Earnings Per Common Share [Abstract]

Earnings Per Common Share

5. Earnings Per Common Share

We calculate basic earnings per common share data using the weighted average number of common shares outstanding during the period. Diluted earnings per share data reflects the potential dilution that would occur if common stock equivalents were exercised or converted to common stock but only to the extent that they are considered dilutive to our earnings. The following table is a reconciliation of basic and diluted earnings per share data for the following periods (amounts in thousands, except per share amounts):

	Three Months Ended March 31,
	2012		2011
Basic
Net income	$	3,846	$	2,019
Weighted average shares outstanding		18,895		18,743
Basic earnings per common share	$	0.20	$	0.11
Diluted
Net income	$	3,846	$	2,019
Weighted average shares outstanding		18,895		18,743
Effect of dilutive securities
Stock options		3		6
Restricted stock		192		135
Weighted average common shares and potential dilutive shares		19,090		18,884
Diluted earnings per common share	$	0.20	$	0.11